Akron’s Human Fibronectin Solution, Virus Inactivated is manufactured following relevant cGMP guidelines for ancillary materials.Product Features: Raw Material•Solvent Detergent (S/D) treatment for virus inactivation of enveloped viruses•Immune Neutralization for inactivation of certain non-enveloped viruses•Affinity Chromatography to reduce prion proteins•Sterile microfiltration to minimize the presence of bacteria and parasitesManufacturing•Type II eCTD MF (#028120) on file with FDA•PMDA (Japan) Eligibility Confirmed (No. 1205004)•Affinity chromatography ligand and sterilized gelatin resin derived from pharmaceutical-grade polygeline solution•Sterile microfiltration followed by aseptic fillingFor Use StatementFor research use or further manufacturing use in ex vivo cell therapy applications. This product is not intended for direct in vivo use or for direct clinical use as a drug, therapeutic, biologic, or medical device.